Skip to main content

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting · Phase 3 · NCT06973187

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

At a glance

Research payments reported, 2025
$161,297
U.S. investigators named
4
Sites paid
4
Planned or actual enrollment
500

About the trial

Sponsor
BeOne Medicines
Tested
Tacabrutideg (drug), Pirtobrutinib (drug)
Dates
Started 2025-09-04; completion 2028-04-17
Results posted
Not yet

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines Ltd. reported $161,297 in research payments for this study in 2025 (7 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Washington University School of Medicine Siteman Cancer Center $69,127
  • Northwest Medical Specialties, PLLC $46,085
  • Titan Health PArtners LLC D/b/a Astera Cancer Care $23,042
  • Cancer Specialists of North Florida $23,042

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.